Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1α,25-dihydroxyvitamin D3
- 31 October 1999
- journal article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 21 (10) , 675-688
- https://doi.org/10.1016/s0192-0561(99)00044-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Tumor-induced immune dysfunction: the macrophage connectionJournal of Leukocyte Biology, 1998
- 1α ,25-Dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2ACancer Immunology, Immunotherapy, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha.The Journal of Experimental Medicine, 1996
- Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancerInternational Journal of Cancer, 1996
- Dendritic cells: from ontogenetic orphans to myelomonocytic descendantsImmunology Today, 1996
- Dendritic Cells in Antitumor Immune ResponsesCellular Immunology, 1996
- Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1995
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- Increased contact hypersensitivity response in mice by topical application of 1?,25-dihydroxyvitamin D3 to elicitation siteArchives of Dermatological Research, 1989